rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Zhengye Biotechnology Holding Limited - Class A

ZYBT · Nasdaq

Health CareBiotechnologyJust started moving

ZYBT stood above a rising 150-day average in 10 of the last 52 weekly readings, including each of the last 10 weeks. It is 16.4% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
10 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
8 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 10 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders8+0 on the quarter
New · exited1 · 1
Reported value$68K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
XTX Topco Ltdadded · filed 14 Aug 202648,865$33K+4,719+10.7%
GEODE CAPITAL MANAGEMENT, LLCunchanged · filed 12 Aug 202629,068$20K00.0%
WINTON GROUP Ltdreduced · filed 7 Aug 202612,730$8,619-20,659−61.9%
UBS Group AGreduced · filed 13 Aug 20267,992$5,410-44−0.5%
ROYAL BANK OF CANADAunchanged · filed 14 Aug 20261,230$1,00000.0%
MORGAN STANLEYreduced · filed 13 Aug 2026248$168-13−5.0%
JPMORGAN CHASE & COnew · filed 12 Aug 2026134$93+134
Caitong International Asset Management Co., Ltdunchanged · filed 5 Aug 20261$100.0%
31 Mar 2025 – 30 Jun 2026
3710Mar 25Jun 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Nobody on record has traded it.

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2024 · to 31 Dec 202449.0%
Operating profit marginFY 2025 · to 31 Dec 2025-60.6%
Free cash flow marginFY 2025 · to 31 Dec 202510.6%
Return on capital employedFY 2025 · to 31 Dec 2025-22.3%
Cash conversionFY 2024 · to 31 Dec 2024363%
Debt to equityFY 2025 · to 31 Dec 20250.04×
Interest coverFY 2025 · to 31 Dec 2025-20.75×
Research spendFY 2025 · to 31 Dec 2025108%
Revenue growthFY 2025 · to 31 Dec 2025-34.8%
Share count trendFY 2025 · to 31 Dec 20253.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.2M
Free cash flowFY 2025 · to 31 Dec 2025$1.8M

Analyst forecasts

No analyst forecasts yet.